Skip to main content

Imv Inc(IMV-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low0.5225
Day High0.6200
Open:0.6200
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest News

IMV Provides an Update on The VITALIZE Trial
Business Wire - Fri Sep 30, 6:05AM CDT
Business Wire
Fri Sep 30, 6:05AM CDT
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today provided an update on the open-label...
IMV Inc. Announces Strategic Reorganization
Business Wire - Thu Sep 15, 6:45AM CDT
Business Wire
Thu Sep 15, 6:45AM CDT
IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a...
IMV Inc. to Present at Two Investor Conferences in September
Business Wire - Thu Sep 1, 6:05AM CDT
Business Wire
Thu Sep 1, 6:05AM CDT
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management...

Latest Articles